{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:50:58Z","timestamp":1792468258559,"version":"4.5.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04316-6","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T17:03:54Z","timestamp":1774199034000},"page":"3594-3614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability"],"prefix":"10.1007","volume":"28","author":[{"given":"Fang","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa Hossam El Din","family":"Moawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Alsaied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6089-240X","authenticated-orcid":false,"given":"Hamza A.","family":"Abdul-Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani A.","family":"Alhadrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ady Ahmed","family":"Azhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar Abdulhakem Abu","family":"Nawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"issue":"3","key":"4316_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4316_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73389-6","volume":"14","author":"T Xie","year":"2024","unstructured":"Xie T, et al. Distant metastasis patterns among lung cancer subtypes and impact of primary tumor resection on survival in metastatic lung cancer using SEER database. Sci Rep. 2024;14(1):22445. https:\/\/doi.org\/10.1038\/s41598-024-73389-6.","journal-title":"Sci Rep"},{"key":"4316_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.annepidem.2024.08.005","volume":"98","author":"CM Kava","year":"2024","unstructured":"Kava CM, Siegel DA, Sabatino SA, Qin J, Richards TB, Henley SJ. Lung cancer incidence, 2019-2020, United States: The potential impact of the COVID-19 pandemic. Ann Epidemiol. 2024;98:44\u201350. https:\/\/doi.org\/10.1016\/j.annepidem.2024.08.005.","journal-title":"Ann Epidemiol"},{"issue":"21","key":"4316_CR4","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2306434.","journal-title":"N Engl J Med"},{"issue":"16","key":"4316_CR5","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, et al. Amivantamab plus Lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391(16):1486\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2403614.","journal-title":"N Engl J Med"},{"issue":"2","key":"4316_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.21037\/tlcr-22-639","volume":"12","author":"M Santarpia","year":"2023","unstructured":"Santarpia M, et al. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review. Transl Lung Cancer Res. 2023;12(2):346\u201368. https:\/\/doi.org\/10.21037\/tlcr-22-639.","journal-title":"Transl Lung Cancer Res"},{"key":"4316_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102572","volume":"118","author":"C Parisi","year":"2023","unstructured":"Parisi C, Mahjoubi L, Gazzah A, Barlesi F. TROP-2 directed antibody-drug conjugates (ADCs): the revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2023;118:102572. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102572.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"4316_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, et al. Trastuzumab Deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386(3):241\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2112431.","journal-title":"N Engl J Med"},{"issue":"19","key":"4316_CR9","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1606774.","journal-title":"N Engl J Med"},{"key":"4316_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114296","volume":"211","author":"M Reck","year":"2024","unstructured":"Reck M, et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer. 2024;211:114296. https:\/\/doi.org\/10.1016\/j.ejca.2024.114296.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4316_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020;19(1):39\u201356. https:\/\/doi.org\/10.1038\/s41573-019-0044-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4316_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"Z-D Shi","year":"2023","unstructured":"Shi Z-D, et al. Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies. Signal Transduct Target Ther. 2023;8(1):113. https:\/\/doi.org\/10.1038\/s41392-023-01383-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"4316_CR13","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","volume":"41","author":"FJ de Miguel","year":"2023","unstructured":"de Miguel FJ, et al. Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell. 2023;41(8):1516-1534.e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.005.","journal-title":"Cancer Cell"},{"issue":"3","key":"4316_CR14","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1042\/BST20211084","volume":"50","author":"B Monterde","year":"2022","unstructured":"Monterde B, Varela I. Role of SWI\/SNF chromatin remodeling genes in lung cancer development. Biochem Soc Trans. 2022;50(3):1143\u201350. https:\/\/doi.org\/10.1042\/BST20211084.","journal-title":"Biochem Soc Trans"},{"issue":"8","key":"4316_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17(8):487\u2013500. https:\/\/doi.org\/10.1038\/nrg.2016.59.","journal-title":"Nat Rev Genet"},{"key":"4316_CR16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-062822-110356","author":"DDG Owens","year":"2024","unstructured":"Owens DDG, Maitland MER, Arrowsmith CH, Barsyte-Lovejoy D. Therapeutic discovery for chromatin complexes: Where do we stand? Annu Rev Cancer Biol. 2024. https:\/\/doi.org\/10.1146\/annurev-cancerbio-062822-110356.","journal-title":"Annu Rev Cancer Biol"},{"issue":"3","key":"4316_CR17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1042\/BST20231141","volume":"52","author":"MC Church","year":"2024","unstructured":"Church MC, Workman JL. The SWI\/SNF chromatin remodeling complex: a critical regulator of metabolism. Biochem Soc Trans. 2024;52(3):1327\u201337. https:\/\/doi.org\/10.1042\/BST20231141.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"4316_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/epigenomes8010007","volume":"8","author":"MR Dreier","year":"2024","unstructured":"Dreier MR, Walia J, de la Serna IL. Targeting SWI\/SNF complexes in cancer: Pharmacological approaches and implications. Epigenomes. 2024;8(1):0007. https:\/\/doi.org\/10.3390\/epigenomes8010007.","journal-title":"Epigenomes"},{"issue":"5","key":"4316_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna10050050","volume":"10","author":"C Suri","year":"2024","unstructured":"Suri C, Swarnkar S, Bhaskar L, Verma HK. Non-coding RNA as a biomarker in lung cancer. Noncoding RNA. 2024;10(5):0050. https:\/\/doi.org\/10.3390\/ncrna10050050.","journal-title":"Noncoding RNA"},{"issue":"9","key":"4316_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004669","volume":"10","author":"N Krishnamurthy","year":"2022","unstructured":"Krishnamurthy N, Kato S, Lippman S, Kurzrock R. Chromatin remodeling (SWI\/SNF) complexes, cancer, and response to immunotherapy. J Immunother Cancer. 2022;10(9):e004669. https:\/\/doi.org\/10.1136\/jitc-2022-004669.","journal-title":"J Immunother Cancer"},{"key":"4316_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1397788","volume":"12","author":"X Lv","year":"2024","unstructured":"Lv X, Yang L, Xie Y, Momeni MR. Non-coding RNAs and exosomal non-coding RNAs in lung cancer: insights into their functions. Front Cell Dev Biol. 2024;12:1397788. https:\/\/doi.org\/10.3389\/fcell.2024.1397788.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"4316_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16212-w","volume":"11","author":"R Vander Velde","year":"2020","unstructured":"Vander Velde R, et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat Commun. 2020;11(1):2393. https:\/\/doi.org\/10.1038\/s41467-020-16212-w.","journal-title":"Nat Commun"},{"key":"4316_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693609","volume":"12","author":"B Zhou","year":"2021","unstructured":"Zhou B, Gao Y, Zhang P, Chu Q. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol. 2021;12:693609. https:\/\/doi.org\/10.3389\/fimmu.2021.693609.","journal-title":"Front Immunol"},{"issue":"22","key":"4316_CR24","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","volume":"81","author":"N Wajapeyee","year":"2021","unstructured":"Wajapeyee N, Gupta R. Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies. Cancer Res. 2021;81(22):5589\u201395. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1606.","journal-title":"Cancer Res"},{"issue":"7","key":"4316_CR25","first-page":"1954","volume":"10","author":"N Darwiche","year":"2020","unstructured":"Darwiche N. Epigenetic mechanisms and the hallmarks of cancer: an intimate affair. Am J Cancer Res. 2020;10(7):1954\u201378.","journal-title":"Am J Cancer Res"},{"key":"4316_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8107318","volume":"2019","author":"Y-X Shi","year":"2019","unstructured":"Shi Y-X, Sheng D-Q, Cheng L, Song X-Y. Current landscape of epigenetics in lung cancer: focus on the mechanism and application. J Oncol. 2019;2019:8107318. https:\/\/doi.org\/10.1155\/2019\/8107318.","journal-title":"J Oncol"},{"issue":"9","key":"4316_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/14737140.2020.1806716","volume":"20","author":"D Franceschini","year":"2020","unstructured":"Franceschini D, et al. Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs. Expert Rev Anticancer Ther. 2020;20(9):743\u201353. https:\/\/doi.org\/10.1080\/14737140.2020.1806716.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"suppl_1","key":"4316_CR28","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl_1):i10\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx703.","journal-title":"Ann Oncol"},{"key":"4316_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.602762","volume":"10","author":"L Wu","year":"2020","unstructured":"Wu L, Ke L, Zhang Z, Yu J, Meng X. Development of EGFR TKIs and options to manage resistance of third-generation EGFR TKI Osimertinib: conventional ways and immune checkpoint inhibitors. Front Oncol. 2020;10:602762. https:\/\/doi.org\/10.3389\/fonc.2020.602762.","journal-title":"Front Oncol"},{"issue":"1","key":"4316_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.21037\/tlcr-22-507","volume":"12","author":"J Vad-Nielsen","year":"2023","unstructured":"Vad-Nielsen J, et al. Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR\/Cas9-mediated gene-disruptions corroborate the MIR141\/MIR200C-ZEB1\/ZEB2-FGFR1 axis in acquired EMT-associated EGFR TKI-resistance in NSCLC cells. Transl Lung Cancer Res. 2023;12(1):42\u201365. https:\/\/doi.org\/10.21037\/tlcr-22-507.","journal-title":"Transl Lung Cancer Res"},{"key":"4316_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01044","volume":"9","author":"X Zhu","year":"2019","unstructured":"Zhu X, Chen L, Liu L, Niu X. EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies. Front Oncol. 2019;9:1044. https:\/\/doi.org\/10.3389\/fonc.2019.01044.","journal-title":"Front Oncol"},{"issue":"1","key":"4316_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto MA, Huang RY-J, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166(1):21\u201345. https:\/\/doi.org\/10.1016\/j.cell.2016.06.028.","journal-title":"Cell"},{"issue":"1","key":"4316_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13441-6","volume":"10","author":"LG Karacosta","year":"2019","unstructured":"Karacosta LG, et al. Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution. Nat Commun. 2019;10(1):5587. https:\/\/doi.org\/10.1038\/s41467-019-13441-6.","journal-title":"Nat Commun"},{"issue":"7","key":"4316_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/1541-7786.MCR-12-0652","volume":"11","author":"H Terai","year":"2013","unstructured":"Terai H, et al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res. 2013;11(7):759\u201367. https:\/\/doi.org\/10.1158\/1541-7786.MCR-12-0652.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"4316_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-1079","volume":"15","author":"SH Lin","year":"2014","unstructured":"Lin SH, et al. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 2014;15(1):1079. https:\/\/doi.org\/10.1186\/1471-2164-15-1079.","journal-title":"BMC Genomics"},{"issue":"5","key":"4316_CR36","doi-asserted-by":"publisher","first-page":"000279","DOI":"10.1136\/esmoopen-2017-000279","volume":"2","author":"CM Connell","year":"2017","unstructured":"Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2(5):000279. https:\/\/doi.org\/10.1136\/esmoopen-2017-000279.","journal-title":"ESMO Open"},{"issue":"1","key":"4316_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pccm.2022.12.001","volume":"1","author":"ME Larsen","year":"2023","unstructured":"Larsen ME, Lyu H, Liu B. HER3-targeted therapeutic antibodies and antibody-drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors. Chin Med J Pulm Crit Care Med. 2023;1(1):11\u20137. https:\/\/doi.org\/10.1016\/j.pccm.2022.12.001.","journal-title":"Chin Med J Pulm Crit Care Med."},{"issue":"1","key":"4316_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","volume":"12","author":"Q Wang","year":"2019","unstructured":"Wang Q, Yang S, Wang K, Sun S-Y. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;12(1):63. https:\/\/doi.org\/10.1186\/s13045-019-0759-9.","journal-title":"J. Hematol Oncol."},{"issue":"17","key":"4316_CR39","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1158\/0008-5472.CAN-19-0024","volume":"79","author":"JH Becker","year":"2019","unstructured":"Becker JH, et al. CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC. Cancer Res. 2019;79(17):4439\u201352. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0024.","journal-title":"Cancer Res"},{"key":"4316_CR40","doi-asserted-by":"publisher","unstructured":"P. Safaric Tepes et al., \u201cAn epigenetic switch regulates the ontogeny of AXL-positive\/EGFR-TKi-resistant cells by modulating miR-335 expression.\u201d eLife, vol. 10, Jul. 2021, https:\/\/doi.org\/10.7554\/eLife.66109.","DOI":"10.7554\/eLife.66109"},{"issue":"1","key":"4316_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41598-017-18527-z","volume":"8","author":"T-F Lee","year":"2018","unstructured":"Lee T-F, Tseng Y-C, Nguyen PA, Li Y-C, Ho C-C, Wu C-W. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas. Sci Rep. 2018;8(1):271. https:\/\/doi.org\/10.1038\/s41598-017-18527-z.","journal-title":"Sci. Rep."},{"issue":"4","key":"4316_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/oncsis.2017.17","volume":"6","author":"KR Jakobsen","year":"2017","unstructured":"Jakobsen KR, et al. MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells. Oncogenesis. 2017;6(4):307. https:\/\/doi.org\/10.1038\/oncsis.2017.17.","journal-title":"Oncogenesis"},{"issue":"20","key":"4316_CR43","doi-asserted-by":"publisher","first-page":"9455","DOI":"10.1158\/0008-5472.CAN-05-1058","volume":"65","author":"S Thomson","year":"2005","unstructured":"Thomson S, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005;65(20):9455\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1058.","journal-title":"Cancer Res"},{"issue":"5","key":"4316_CR44","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.21037\/tlcr-20-522","volume":"9","author":"MS Clement","year":"2020","unstructured":"Clement MS, Gammelgaard KR, Nielsen AL, Sorensen BS. Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells. Transl Lung Cancer Res. 2020;9(5):1904\u201314. https:\/\/doi.org\/10.21037\/tlcr-20-522.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"4316_CR45","doi-asserted-by":"publisher","first-page":"e0147344","DOI":"10.1371\/journal.pone.0147344","volume":"11","author":"T Yoshida","year":"2016","unstructured":"Yoshida T, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE. 2016;11(1):e0147344. https:\/\/doi.org\/10.1371\/journal.pone.0147344.","journal-title":"PLoS ONE."},{"issue":"5","key":"4316_CR46","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41388-018-0482-y","volume":"38","author":"ZA Yochum","year":"2019","unstructured":"Yochum ZA, et al. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 2019;38(5):656\u201370. https:\/\/doi.org\/10.1038\/s41388-018-0482-y.","journal-title":"Oncogene"},{"issue":"5","key":"4316_CR47","doi-asserted-by":"publisher","first-page":"189413","DOI":"10.1016\/j.bbcan.2025.189413","volume":"1880","author":"S Liu","year":"2025","unstructured":"Liu S, Xu T, Cao X, Li H, Jin R. Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches. Biochim Biophys Acta Rev Cancer. 2025;1880(5):189413. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189413.","journal-title":"Biochim. Biophys. Acta Rev. Cancer."},{"issue":"1","key":"4316_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3892\/mco.2025.2857","volume":"23","author":"H Zhang","year":"2025","unstructured":"Zhang H, Gao H, Gao P, Liu H, Chen J. Molecular mechanisms and therapeutic strategies for small-cell lung cancer transformation after TKI therapy in EGFR-mutated lung adenocarcinoma (Review). Mol Clin Oncol. 2025;23(1):62. https:\/\/doi.org\/10.3892\/mco.2025.2857.","journal-title":"Mol. Clin. Oncol."},{"issue":"8","key":"4316_CR49","doi-asserted-by":"publisher","first-page":"e70458","DOI":"10.1002\/ctm2.70458","volume":"15","author":"F Meng","year":"2025","unstructured":"Meng F, et al. Persistent lineage plasticity driving lung cancer development and progression. Clin Transl Med. 2025;15(8):e70458. https:\/\/doi.org\/10.1002\/ctm2.70458.","journal-title":"Clin. Transl. Med."},{"issue":"10","key":"4316_CR50","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.002.","journal-title":"J Thorac Oncol"},{"key":"4316_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1006480","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, et al. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers. Front Endocrinol (Lausanne). 2022;13:1006480. https:\/\/doi.org\/10.3389\/fendo.2022.1006480.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"4316_CR52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/PGP.0000000000000388","volume":"37","author":"A Gut","year":"2018","unstructured":"Gut A, Moch H, Choschzick M. SOX2 gene amplification and overexpression is linked to HPV-positive vulvar carcinomas. Int J Gynecol Pathol. 2018;37(1):68\u201373. https:\/\/doi.org\/10.1097\/PGP.0000000000000388.","journal-title":"Int J Gynecol Pathol"},{"issue":"9","key":"4316_CR53","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1097\/JTO.0000000000000571","volume":"10","author":"PA Levin","year":"2015","unstructured":"Levin PA, Mayer M, Hoskin S, Sailors J, Oliver DH, Gerber DE. Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition. J Thorac Oncol. 2015;10(9):e86\u20138. https:\/\/doi.org\/10.1097\/JTO.0000000000000571.","journal-title":"J Thorac Oncol"},{"key":"4316_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1029282","volume":"12","author":"M-H Yang","year":"2022","unstructured":"Yang M-H, Yu J, Cai C-L, Li W. Small cell lung cancer transformation and tumor heterogeneity after sequential targeted therapy and immunotherapy in EGFR-mutant non-small cell lung cancer: a case report. Front Oncol. 2022;12:1029282. https:\/\/doi.org\/10.3389\/fonc.2022.1029282.","journal-title":"Front Oncol"},{"issue":"4","key":"4316_CR55","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jtho.2016.01.012","volume":"11","author":"PA Bunn","year":"2016","unstructured":"Bunn PA, et al. Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? J Thorac Oncol. 2016;11(4):453\u201374. https:\/\/doi.org\/10.1016\/j.jtho.2016.01.012.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4316_CR56","doi-asserted-by":"publisher","first-page":"837","DOI":"10.21037\/tlcr-22-867","volume":"12","author":"CB Meador","year":"2023","unstructured":"Meador CB, Piotrowska Z. Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review. Transl Lung Cancer Res. 2023;12(4):837\u201356. https:\/\/doi.org\/10.21037\/tlcr-22-867.","journal-title":"Transl Lung Cancer Res"},{"key":"4316_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101358","author":"Y Pei","year":"2025","unstructured":"Pei Y, et al. The role of NRF2 in human cancers: Pre-clinical insights paving the way for clinical trials. J Pharma Analy. 2025. https:\/\/doi.org\/10.1016\/j.jpha.2025.101358.","journal-title":"J Pharma Analy"},{"issue":"8","key":"4316_CR58","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.ccell.2025.06.011","volume":"43","author":"A Galan-Cobo","year":"2025","unstructured":"Galan-Cobo A, et al. KEAP1 and STK11\/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer Cell. 2025;43(8):1530-1548.e9. https:\/\/doi.org\/10.1016\/j.ccell.2025.06.011.","journal-title":"Cancer Cell"},{"issue":"1","key":"4316_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022;7(1):329. https:\/\/doi.org\/10.1038\/s41392-022-01168-8.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4316_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0801-5","volume":"17","author":"Q Jiao","year":"2018","unstructured":"Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang Y-S. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17(1):36. https:\/\/doi.org\/10.1186\/s12943-018-0801-5.","journal-title":"Mol Cancer"},{"issue":"Supplement 1","key":"4316_CR61","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1182\/blood-2023-188004","volume":"142","author":"J Qiao","year":"2023","unstructured":"Qiao J, et al. The resistance mechanism to BET-Protac in multiple myeloma. Blood. 2023;142(Supplement 1):6584\u20136584. https:\/\/doi.org\/10.1182\/blood-2023-188004.","journal-title":"Blood"},{"issue":"2","key":"4316_CR62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5732\/cjc.011.10466","volume":"31","author":"Y-L Sun","year":"2012","unstructured":"Sun Y-L, Patel A, Kumar P, Chen Z-S. Role of ABC transporters in cancer chemotherapy. Chin J Cancer. 2012;31(2):51\u20137. https:\/\/doi.org\/10.5732\/cjc.011.10466.","journal-title":"Chin J Cancer"},{"key":"4316_CR63","volume-title":"Breast cancer","author":"AL Berg","year":"2022","unstructured":"Berg AL, Rowson-Hodel A, Wheeler MR, Hu M, Free SR, Carraway KL. Engaging the lysosome and lysosome-dependent cell death in cancer. In: Mayrovitz HN, editor. Breast cancer. Brisbane (AU): Exon Publications; 2022."},{"key":"4316_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124392","author":"J Hrab\u011bta","year":"2020","unstructured":"Hrab\u011bta J, Belhajov\u00e1 M, \u0160ubrtov\u00e1 H, Merlos Rodrigo MA, Heger Z, Eckschlager T. Drug sequestration in lysosomes as one of the mechanisms of chemoresistance of cancer cells and the possibilities of its inhibition. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21124392.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"4316_CR65","doi-asserted-by":"publisher","first-page":"39460","DOI":"10.18632\/oncotarget.17063","volume":"8","author":"RT Burke","year":"2017","unstructured":"Burke RT, Marcus JM, Orth JD. Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells. Oncotarget. 2017;8(24):39460\u201375. https:\/\/doi.org\/10.18632\/oncotarget.17063.","journal-title":"Oncotarget"},{"issue":"1","key":"4316_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54852-4","volume":"15","author":"HE Greenwood","year":"2024","unstructured":"Greenwood HE, et al. Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography. Nat Commun. 2024;15(1):10484. https:\/\/doi.org\/10.1038\/s41467-024-54852-4.","journal-title":"Nat Commun"},{"issue":"3","key":"4316_CR67","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1158\/1078-0432.CCR-20-1985","volume":"27","author":"A Singh","year":"2021","unstructured":"Singh A, et al. NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes. Clin Cancer Res. 2021;27(3):877\u201388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1985.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4316_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. https:\/\/doi.org\/10.1038\/s41467-017-01062-w.","journal-title":"Nat Commun"},{"key":"4316_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1512509","volume":"16","author":"X Han","year":"2025","unstructured":"Han X, et al. The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies. Front Immunol. 2025;16:1512509. https:\/\/doi.org\/10.3389\/fimmu.2025.1512509.","journal-title":"Front Immunol"},{"issue":"12","key":"4316_CR70","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7(12):1420\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0593.","journal-title":"Cancer Discov"},{"issue":"9","key":"4316_CR71","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1604958.","journal-title":"N Engl J Med"},{"key":"4316_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/cells14080587","author":"P Zieli\u0144ski","year":"2025","unstructured":"Zieli\u0144ski P, et al. Resistance in lung cancer immunotherapy and how to overcome it: insights from the genetics perspective and combination therapies approach. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14080587.","journal-title":"Cells"},{"issue":"6","key":"4316_CR73","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1008824","volume":"4","author":"R Bellucci","year":"2015","unstructured":"Bellucci R, et al. Interferon-\u03b3-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015;4(6):e1008824. https:\/\/doi.org\/10.1080\/2162402X.2015.1008824.","journal-title":"Oncoimmunology"},{"issue":"2","key":"4316_CR74","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1223.","journal-title":"Cancer Discov"},{"key":"4316_CR75","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.intimp.2017.03.015","volume":"46","author":"Q Wang","year":"2017","unstructured":"Wang Q, Wu X. Primary and acquired resistance to PD-1\/PD-L1 blockade in cancer treatment. Int Immunopharmacol. 2017;46:210\u20139. https:\/\/doi.org\/10.1016\/j.intimp.2017.03.015.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"4316_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176181","volume":"12","author":"LA Albacker","year":"2017","unstructured":"Albacker LA, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS ONE. 2017;12(11):e0176181. https:\/\/doi.org\/10.1371\/journal.pone.0176181.","journal-title":"PLoS ONE"},{"issue":"6","key":"4316_CR77","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/1061186X.2025.2453730","volume":"33","author":"Y Feng","year":"2025","unstructured":"Feng Y, et al. Interactions and communications in lung tumour microenvironment: chemo\/radiotherapy resistance mechanisms and therapeutic targets. J Drug Target. 2025;33(6):817\u201336. https:\/\/doi.org\/10.1080\/1061186X.2025.2453730.","journal-title":"J Drug Target"},{"issue":"23","key":"4316_CR78","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.1158\/1078-0432.CCR-24-1690","volume":"30","author":"E Timperi","year":"2024","unstructured":"Timperi E, et al. At the interface of tumor-associated macrophages and fibroblasts: immune-suppressive networks and emerging exploitable targets. Clin Cancer Res. 2024;30(23):5242\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1690.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4316_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02599-7","volume":"22","author":"B Feng","year":"2022","unstructured":"Feng B, Wu J, Shen B, Jiang F, Feng J. Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures. Cancer Cell Int. 2022;22(1):166. https:\/\/doi.org\/10.1186\/s12935-022-02599-7.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"4316_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-019-1329-2","volume":"37","author":"R Tamura","year":"2019","unstructured":"Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol. 2019;37(1):2. https:\/\/doi.org\/10.1007\/s12032-019-1329-2.","journal-title":"Med Oncol"},{"issue":"10","key":"4316_CR81","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"C-H Heldin","year":"2004","unstructured":"Heldin C-H, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806\u201313. https:\/\/doi.org\/10.1038\/nrc1456.","journal-title":"Nat Rev Cancer"},{"key":"4316_CR82","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-3-319-91287-5_27","volume":"1072","author":"P Vaupel","year":"2018","unstructured":"Vaupel P, Multhoff G. Hypoxia-\/HIF-1\u03b1-driven factors of the tumor microenvironment impeding antitumor immune responses and promoting malignant progression. Adv Exp Med Biol. 2018;1072:171\u20135. https:\/\/doi.org\/10.1007\/978-3-319-91287-5_27.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"4316_CR83","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.62347\/LXOS2662","volume":"14","author":"H Xue","year":"2024","unstructured":"Xue H. The role of m6A methylation in targeted therapy resistance in lung cancer. Am J Cancer Res. 2024;14(6):2994\u20133009. https:\/\/doi.org\/10.62347\/LXOS2662.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"4316_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01782-2","volume":"22","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, et al. The role of m6A methylation in therapy resistance in cancer. Mol Cancer. 2023;22(1):91. https:\/\/doi.org\/10.1186\/s12943-023-01782-2.","journal-title":"Mol Cancer"},{"key":"4316_CR85","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8114","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Liu S, Zhao T, Dang C. METTL3-mediated m6A modification of Bcl-2 mRNA promotes non-small cell lung cancer progression. Oncol Rep. 2021. https:\/\/doi.org\/10.3892\/or.2021.8114.","journal-title":"Oncol Rep"},{"issue":"5","key":"4316_CR86","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/jcmm.16114","volume":"25","author":"F Gao","year":"2021","unstructured":"Gao F, et al. RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K\/AKT pathway in lung adenocarcinoma. J Cell Mol Med. 2021;25(5):2418\u201325. https:\/\/doi.org\/10.1111\/jcmm.16114.","journal-title":"J Cell Mol Med"},{"key":"4316_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102230","volume":"51","author":"T Huang","year":"2025","unstructured":"Huang T, et al. m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway. Transl Oncol. 2025;51:102230. https:\/\/doi.org\/10.1016\/j.tranon.2024.102230.","journal-title":"Transl Oncol"},{"issue":"1","key":"4316_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00840-4","volume":"20","author":"A Maharati","year":"2022","unstructured":"Maharati A, Zanguei AS, Khalili-Tanha G, Moghbeli M. MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells. Cell Commun Signal. 2022;20(1):27. https:\/\/doi.org\/10.1186\/s12964-022-00840-4.","journal-title":"Cell Commun Signal"},{"key":"4316_CR89","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2025.5773","author":"Z Li","year":"2025","unstructured":"Li Z, Zhang H, Chen Z, Wu G, Guo W, Li Y. MicroRNA-21: a potential therapeutic target in lung cancer (Review). Int J Oncol. 2025. https:\/\/doi.org\/10.3892\/ijo.2025.5773.","journal-title":"Int J Oncol"},{"key":"4316_CR90","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2147\/OTT.S66502","volume":"7","author":"X Cheng","year":"2014","unstructured":"Cheng X, Chen H. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther. 2014;7:1689\u2013704. https:\/\/doi.org\/10.2147\/OTT.S66502.","journal-title":"Onco Targets Ther"},{"key":"4316_CR91","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.lungcan.2020.08.010","volume":"148","author":"K Suda","year":"2020","unstructured":"Suda K, et al. Spatial heterogeneity of acquired resistance mechanisms to 1st\/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. Lung Cancer. 2020;148:100\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.010.","journal-title":"Lung Cancer"},{"issue":"4","key":"4316_CR92","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/jor3040021","volume":"3","author":"K Kobayashi","year":"2023","unstructured":"Kobayashi K. Primary resistance to EGFR tyrosine kinase inhibitors (TKIs): contexts and comparisons in EGFR-mutated lung cancer. J Orthop Res. 2023;3(4):223\u201336. https:\/\/doi.org\/10.3390\/jor3040021.","journal-title":"J Orthop Res"},{"issue":"1","key":"4316_CR93","doi-asserted-by":"publisher","first-page":"56","DOI":"10.18632\/oncotarget.2695","volume":"6","author":"FP Vendetti","year":"2015","unstructured":"Vendetti FP, et al. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 2015;6(1):56\u201370. https:\/\/doi.org\/10.18632\/oncotarget.2695.","journal-title":"Oncotarget"},{"issue":"6","key":"4316_CR94","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","volume":"171","author":"MJ Topper","year":"2017","unstructured":"Topper MJ, et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell. 2017;171(6):1284-1300.e21. https:\/\/doi.org\/10.1016\/j.cell.2017.10.022.","journal-title":"Cell"},{"key":"4316_CR95","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00151","author":"S-F Su","year":"2021","unstructured":"Su S-F, et al. Genome-wide epigenetic landscape of lung adenocarcinoma links HOXB9 DNA methylation to intrinsic EGFR-TKI resistance and heterogeneous responses. JCO Precis Oncol. 2021. https:\/\/doi.org\/10.1200\/PO.20.00151.","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"4316_CR96","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/sj.bjc.6603024","volume":"94","author":"RM Glasspool","year":"2006","unstructured":"Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer. 2006;94(8):1087\u201392. https:\/\/doi.org\/10.1038\/sj.bjc.6603024.","journal-title":"Br J Cancer"},{"issue":"12","key":"4316_CR97","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41416-023-02267-1","volume":"128","author":"JJ Luke","year":"2023","unstructured":"Luke JJ, et al. Phase I\/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. Br J Cancer. 2023;128(12):2227\u201335. https:\/\/doi.org\/10.1038\/s41416-023-02267-1.","journal-title":"Br J Cancer"},{"key":"4316_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01443","volume":"9","author":"C Fazio","year":"2018","unstructured":"Fazio C, et al. Immunomodulatory properties of DNA hypomethylating agents: selecting the optimal epigenetic partner for cancer immunotherapy. Front Pharmacol. 2018;9:1443. https:\/\/doi.org\/10.3389\/fphar.2018.01443.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4316_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02630-w","volume":"9","author":"N Luo","year":"2018","unstructured":"Luo N, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun. 2018;9(1):248. https:\/\/doi.org\/10.1038\/s41467-017-02630-w.","journal-title":"Nat Commun"},{"issue":"6","key":"4316_CR100","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.401","volume":"4","author":"S Ramazi","year":"2023","unstructured":"Ramazi S, Dadzadi M, Sahafnejad Z, Allahverdi A. Epigenetic regulation in lung cancer. MedComm. 2023;4(6):e401. https:\/\/doi.org\/10.1002\/mco2.401.","journal-title":"MedComm"},{"issue":"1","key":"4316_CR101","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.critrevonc.2008.03.002","volume":"68","author":"C Gridelli","year":"2008","unstructured":"Gridelli C, Rossi A, Maione P. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 2008;68(1):29\u201336. https:\/\/doi.org\/10.1016\/j.critrevonc.2008.03.002.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4316_CR102","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejca.2016.09.010","volume":"68","author":"M de Charette","year":"2016","unstructured":"de Charette M, Marabelle A, Houot R. Turning tumour cells into antigen presenting cells: the next step to improve cancer immunotherapy? Eur J Cancer. 2016;68:134\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2016.09.010.","journal-title":"Eur J Cancer"},{"key":"4316_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00298","volume":"6","author":"CC Oliveira","year":"2015","unstructured":"Oliveira CC, van Hall T. Alternative antigen processing for MHC class I: multiple roads lead to Rome. Front Immunol. 2015;6:298. https:\/\/doi.org\/10.3389\/fimmu.2015.00298.","journal-title":"Front Immunol"},{"issue":"2","key":"4316_CR104","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.lungcan.2014.02.011","volume":"84","author":"N Reguart","year":"2014","unstructured":"Reguart N, et al. Phase I\/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer. 2014;84(2):161\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2014.02.011.","journal-title":"Lung Cancer"},{"issue":"4","key":"4316_CR105","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-20-3305","volume":"27","author":"MD Hellmann","year":"2021","unstructured":"Hellmann MD, et al. Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy. Clin Cancer Res. 2021;27(4):1019\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3305.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"4316_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11203-8","volume":"23","author":"T Tokito","year":"2024","unstructured":"Tokito T, et al. Epacadostat plus Pembrolizumab versus placebo plus Pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: A randomized, double-blind phase 2 study. BMC Cancer. 2024;23(Suppl 1):1251. https:\/\/doi.org\/10.1186\/s12885-023-11203-8.","journal-title":"BMC Cancer"},{"issue":"3","key":"4316_CR107","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00262-016-1935-1","volume":"66","author":"H-F Wang","year":"2017","unstructured":"Wang H-F, et al. Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro. Cancer Immunol Immunother. 2017;66(3):355\u201366. https:\/\/doi.org\/10.1007\/s00262-016-1935-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"4316_CR108","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","volume":"16","author":"H Zhu","year":"2016","unstructured":"Zhu H, et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016;16(11):2829\u201337. https:\/\/doi.org\/10.1016\/j.celrep.2016.08.032.","journal-title":"Cell Rep"},{"issue":"1","key":"4316_CR109","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.tcb.2018.07.006","volume":"29","author":"H Loo Yau","year":"2019","unstructured":"Loo Yau H, Ettayebi I, De Carvalho DD. The cancer epigenome: Exploiting its vulnerabilities for immunotherapy. Trends Cell Biol. 2019;29(1):31\u201343. https:\/\/doi.org\/10.1016\/j.tcb.2018.07.006.","journal-title":"Trends Cell Biol"},{"issue":"13\u201314","key":"4316_CR110","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.drudis.2011.05.012","volume":"16","author":"FAA Kwa","year":"2011","unstructured":"Kwa FAA, Balcerczyk A, Licciardi P, El-Osta A, Karagiannis TC. Chromatin modifying agents - the cutting edge of anticancer therapy. Drug Discov Today. 2011;16(13\u201314):543\u20137. https:\/\/doi.org\/10.1016\/j.drudis.2011.05.012.","journal-title":"Drug Discov Today"},{"issue":"2","key":"4316_CR111","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000744","volume":"4","author":"K Klein","year":"2018","unstructured":"Klein K. Bromodomain protein inhibition: A novel therapeutic strategy in rheumatic diseases. RMD Open. 2018;4(2):e000744. https:\/\/doi.org\/10.1136\/rmdopen-2018-000744.","journal-title":"RMD Open"},{"issue":"8","key":"4316_CR112","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","volume":"28","author":"DB Doroshow","year":"2017","unstructured":"Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28(8):1776\u201387. https:\/\/doi.org\/10.1093\/annonc\/mdx157.","journal-title":"Ann Oncol"},{"issue":"47","key":"4316_CR113","doi-asserted-by":"publisher","first-page":"77378","DOI":"10.18632\/oncotarget.12671","volume":"7","author":"F Kato","year":"2016","unstructured":"Kato F, et al. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Oncotarget. 2016;7(47):77378\u201388. https:\/\/doi.org\/10.18632\/oncotarget.12671.","journal-title":"Oncotarget"},{"issue":"3","key":"4316_CR114","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"J-H Cha","year":"2019","unstructured":"Cha J-H, Chan L-C, Li C-W, Hsu JL, Hung M-C. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359\u201370. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.030.","journal-title":"Mol Cell"},{"issue":"8","key":"4316_CR115","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1541-7786.MCR-23-0599","volume":"22","author":"JP Plotnik","year":"2024","unstructured":"Plotnik JP, et al. MYC family amplification dictates sensitivity to BET bromodomain protein inhibitor Mivebresib (ABBV075) in small-cell lung cancer. Mol Cancer Res. 2024;22(8):689\u201398. https:\/\/doi.org\/10.1158\/1541-7786.MCR-23-0599.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"4316_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz092","volume":"4","author":"P Martin-Romano","year":"2020","unstructured":"Martin-Romano P, Baldini C, Postel-Vinay S. How much can we bet on activity of BET inhibitors beyond NUT-Midline carcinoma? JNCI Cancer Spectr. 2020;4(2):pkz092. https:\/\/doi.org\/10.1093\/jncics\/pkz092.","journal-title":"JNCI Cancer Spectr"},{"issue":"24","key":"4316_CR117","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","volume":"80","author":"M-L Eich","year":"2020","unstructured":"Eich M-L, Athar M, Ferguson JE, Varambally S. EZH2-Targeted therapies in cancer: hype or a reality. Cancer Res. 2020;80(24):5449\u201358. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2147.","journal-title":"Cancer Res"},{"issue":"8","key":"4316_CR118","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1158\/2159-8290.CD-20-0913","volume":"11","author":"NR Mahadevan","year":"2021","unstructured":"Mahadevan NR, et al. Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity. Cancer Discov. 2021;11(8):1952\u201369. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0913.","journal-title":"Cancer Discov"},{"issue":"3","key":"4316_CR119","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/onco2030013","volume":"2","author":"U Testa","year":"2022","unstructured":"Testa U, Pelosi E, Castelli G. Genomic and gene expression studies helped to define the heterogeneity of small-cell lung cancer and other lung neuroendocrine tumors and to identify new therapeutic targets. Onco. 2022;2(3):186\u2013244. https:\/\/doi.org\/10.3390\/onco2030013.","journal-title":"Onco"},{"key":"4316_CR120","doi-asserted-by":"publisher","DOI":"10.1101\/2023.06.06.543919","author":"TJ DuCote","year":"2023","unstructured":"DuCote TJ, et al. EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas. BioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.06.06.543919.","journal-title":"BioRxiv"},{"issue":"6","key":"4316_CR121","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s43018-023-00553-8","volume":"4","author":"L Chibaya","year":"2023","unstructured":"Chibaya L, et al. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Nat Cancer. 2023;4(6):872\u201392. https:\/\/doi.org\/10.1038\/s43018-023-00553-8.","journal-title":"Nat Cancer"},{"issue":"16_suppl","key":"4316_CR122","doi-asserted-by":"publisher","first-page":"TPS10077","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS10077","volume":"42","author":"JS Yi","year":"2024","unstructured":"Yi JS, et al. TAZNI: A phase I\/II combination trial of Tazemetostat with Nivolumab and Ipilimumab for children with INI1-negative or SMARCA4-deficient tumors. J Clin Oncol. 2024;42(16_suppl):TPS10077\u2013TPS10077. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS10077.","journal-title":"J Clin Oncol"},{"key":"4316_CR123","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2020.09.003","volume":"495","author":"C Quan","year":"2020","unstructured":"Quan C, et al. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Lett. 2020;495:41\u201352. https:\/\/doi.org\/10.1016\/j.canlet.2020.09.003.","journal-title":"Cancer Lett"},{"issue":"6","key":"4316_CR124","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/1878-0261.13124","volume":"16","author":"W Yan","year":"2022","unstructured":"Yan W, et al. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state. Mol Oncol. 2022;16(6):1309\u201328. https:\/\/doi.org\/10.1002\/1878-0261.13124.","journal-title":"Mol Oncol"},{"key":"4316_CR125","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aau2922","author":"A Augert","year":"2019","unstructured":"Augert A, et al. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci Signal. 2019. https:\/\/doi.org\/10.1126\/scisignal.aau2922.","journal-title":"Sci Signal"},{"issue":"0","key":"4316_CR126","doi-asserted-by":"publisher","first-page":"0","DOI":"10.21037\/tlcr-23-40","volume":"0","author":"M Sattler","year":"2023","unstructured":"Sattler M, Salgia R. LSD1-targeted therapy\u2014a multi-purpose key to unlock immunotherapy in small cell lung cancer. Transl Lung Cancer Res. 2023;0(0):0\u20130. https:\/\/doi.org\/10.21037\/tlcr-23-40.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"4316_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31998-7","volume":"13","author":"H-Y Chen","year":"2022","unstructured":"Chen H-Y, et al. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1. Nat Commun. 2022;13(1):4998. https:\/\/doi.org\/10.1038\/s41467-022-31998-7.","journal-title":"Nat Commun"},{"issue":"6278","key":"4316_CR128","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","volume":"351","author":"GV Kryukov","year":"2016","unstructured":"Kryukov GV, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214\u20138. https:\/\/doi.org\/10.1126\/science.aad5214.","journal-title":"Science"},{"issue":"7","key":"4316_CR129","doi-asserted-by":"publisher","first-page":"6932","DOI":"10.1021\/acs.jmedchem.4c03121","volume":"68","author":"LH Pettus","year":"2025","unstructured":"Pettus LH, et al. Discovery of AMG 193, an MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancers. J Med Chem. 2025;68(7):6932\u201354. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c03121.","journal-title":"J Med Chem"},{"issue":"2","key":"4316_CR130","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2019.07.003","volume":"36","author":"JY Fong","year":"2019","unstructured":"Fong JY, et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell. 2019;36(2):194-209.e9. https:\/\/doi.org\/10.1016\/j.ccell.2019.07.003.","journal-title":"Cancer Cell"},{"key":"4316_CR131","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz244","author":"LL Siu","year":"2019","unstructured":"Siu LL, et al. METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours. Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdz244.","journal-title":"Ann Oncol"},{"key":"4316_CR132","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.biochi.2013.10.021","volume":"97","author":"R Elakoum","year":"2014","unstructured":"Elakoum R, et al. CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features. Biochimie. 2014;97:210\u20138. https:\/\/doi.org\/10.1016\/j.biochi.2013.10.021.","journal-title":"Biochimie"},{"issue":"4","key":"4316_CR133","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1158\/2159-8290.CD-15-0754","volume":"6","author":"H Ogiwara","year":"2016","unstructured":"Ogiwara H, et al. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Discov. 2016;6(4):430\u201345. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0754.","journal-title":"Cancer Discov"},{"issue":"4","key":"4316_CR134","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/2159-8290.CD-16-0163","volume":"6","author":"C Kadoch","year":"2016","unstructured":"Kadoch C. Lifting up the HAT: synthetic lethal screening reveals a novel vulnerability at the CBP-p300 axis. Cancer Discov. 2016;6(4):350\u20132. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0163.","journal-title":"Cancer Discov"},{"key":"4316_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108847","volume":"164","author":"D-D Shen","year":"2025","unstructured":"Shen D-D, et al. The LSD1\/HDAC dual-target inhibitor for cancer therapy: challenge and opportunity. Bioorg Chem. 2025;164:108847. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108847.","journal-title":"Bioorg Chem"},{"issue":"11","key":"4316_CR136","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1158\/2159-8290.CD-23-1212","volume":"14","author":"S Wang","year":"2024","unstructured":"Wang S, et al. The N6-methyladenosine epitranscriptomic landscape of lung adenocarcinoma. Cancer Discov. 2024;14(11):2279\u201399. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1212.","journal-title":"Cancer Discov"},{"issue":"1","key":"4316_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03073-0","volume":"43","author":"X Hua","year":"2024","unstructured":"Hua X, et al. ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages. J Exp Clin Cancer Res. 2024;43(1):164. https:\/\/doi.org\/10.1186\/s13046-024-03073-0.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"4316_CR138","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/13543776.2025.2477482","volume":"35","author":"Z Dong","year":"2025","unstructured":"Dong Z, Huang Y, Xia W, Liao Y, Yang C-G. A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017-present. Expert Opin Ther Pat. 2025;35(6):533\u201342. https:\/\/doi.org\/10.1080\/13543776.2025.2477482.","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"4316_CR139","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.2993","volume":"226","author":"JK Watts","year":"2011","unstructured":"Watts JK, Corey DR. Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic. J Pathol. 2011;226(2):365.","journal-title":"J Pathol."},{"issue":"1","key":"4316_CR140","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1021\/acsami.8b18288","volume":"11","author":"N Gong","year":"2019","unstructured":"Gong N, Teng X, Li J, Liang X-J. Antisense oligonucleotide-conjugated nanostructure-targeting lncRNA MALAT1 inhibits cancer metastasis. ACS Appl Mater Interfaces. 2019;11(1):37\u201342. https:\/\/doi.org\/10.1021\/acsami.8b18288.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4316_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1608480","volume":"13","author":"P Zhang","year":"2025","unstructured":"Zhang P, et al. Engineered exosomes: a promising design platform for overcoming cancer therapy resistance. Front Cell Dev Biol. 2025;13:1608480. https:\/\/doi.org\/10.3389\/fcell.2025.1608480.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"4316_CR142","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cllc.2023.03.003","volume":"24","author":"CX Wei","year":"2023","unstructured":"Wei CX, et al. A brief report of a phase II trial evaluating efficacy and safety of hypomethylating agent guadecitabine in combination with carboplatin in extensive stage small cell lung cancer. Clin Lung Cancer. 2023;24(4):347\u201352. https:\/\/doi.org\/10.1016\/j.cllc.2023.03.003.","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"4316_CR143","doi-asserted-by":"publisher","first-page":"S722","DOI":"10.1016\/S1556-0864(21)01892-X","volume":"16","author":"SP Aix","year":"2021","unstructured":"Aix SP, et al. 50P A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): updated results. J Thorac Oncol. 2021;16(4):S722\u20133. https:\/\/doi.org\/10.1016\/S1556-0864(21)01892-X.","journal-title":"J Thorac Oncol"},{"issue":"7_Supplement","key":"4316_CR144","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1158\/1538-7445.AM2023-2779","volume":"83","author":"L Waters","year":"2023","unstructured":"Waters L, et al. Abstract 2779: identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers. Cancer Res. 2023;83(7_Supplement):2779\u20132779. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-2779.","journal-title":"Cancer Res"},{"issue":"12","key":"4316_CR145","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","volume":"35","author":"J Rodon","year":"2024","unstructured":"Rodon J, et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol. 2024;35(12):1138\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2339.","journal-title":"Ann Oncol"},{"key":"4316_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174079","author":"J Hilton","year":"2022","unstructured":"Hilton J, et al. BMS-986158, a small molecule inhibitor of the bromodomain and extraterminal domain proteins, in patients with selected advanced solid tumors: results from a phase 1\/2a trial. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14174079.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4316_CR147","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7175","volume":"13","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: a multicohort, open-label, phase II trial with biomarker analysis. Cancer Med. 2024;13(7):e7175. https:\/\/doi.org\/10.1002\/cam4.7175.","journal-title":"Cancer Med"},{"issue":"18","key":"4316_CR148","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.2011.38.9411","volume":"30","author":"SE Witta","year":"2012","unstructured":"Witta SE, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012;30(18):2248\u201355. https:\/\/doi.org\/10.1200\/JCO.2011.38.9411.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4316_CR149","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","volume":"18","author":"M Candelaria","year":"2007","unstructured":"Candelaria M, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18(9):1529\u201338. https:\/\/doi.org\/10.1093\/annonc\/mdm204.","journal-title":"Ann Oncol"},{"issue":"12","key":"4316_CR150","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/s41416-020-01077-z","volume":"123","author":"M Ameratunga","year":"2020","unstructured":"Ameratunga M, et al. First-in-human phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020;123(12):1730\u20136. https:\/\/doi.org\/10.1038\/s41416-020-01077-z.","journal-title":"Br J Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04316-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04316-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04316-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:22:15Z","timestamp":1787455335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04316-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":150,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4316"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04316-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final manuscript for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}